Will changing what I eat bring my color back?
No food or eating pattern has been shown to repigment skin or stop vitiligo spreading. I read two vitiligo guidelines and the American Academy of Dermatology treatment page. They map out what is used to treat vitiligo. Creams, light treatment, pills and surgical options are on those maps. Food is not. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Those maps are where a dermatologist starts. I read them side by side, and food never enters the treatment list. Not in the UK guidance, not in the international recommendations, and not in the US patient pages.
Considerations
- Depends on you
A guideline that stays silent on food is not the same as a trial that tested food and found nothing. Each of these documents is written for a population rather than for you.
Questions for your dermatologist
I have ___ in my family or medical history. Does that mean I should look at what I eat?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does cutting out ___ change what you would do for my vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Which nutrients have actually been studied in vitiligo?
A short list, and every study tested a capsule rather than a meal. The two reviews I read between them name vitamins B12, D and E, folic acid, ginkgo biloba and Polypodium leucotomos. Evidence Evidence Evidence Evidence
- Ginkgo biloba: Cochrane analyzed one trial of 47 people in which oral ginkgo did better than placebo.
- Polypodium leucotomos: a trial of 50 people added it to narrowband UVB. Head and neck repigmentation was 44 per cent, against 27 per cent with placebo, reported at P = 0.06.
- Zinc and copper: a meta-analysis of 41 studies found lower average blood levels in people with vitiligo.
- Vitamins B12, D, E and folic acid: named in the reviews as tested, with no result the reviews call established.
Why this matters
- Sources cited, not yet graded
Whether a diet, a supplement or a vitamin helps is one of the questions readers bring here most often. What I found is small trials, and adjunct to light treatment at most. The Polypodium figure came alongside narrowband UVB, not on its own. Lower average blood zinc is an association across groups.
Considerations
- Depends on you
A P value of 0.06 does not establish an effect. A group average does not establish your own level or a reason to supplement. I looked for a study comparing more of a food with a capsule, and found none.
Questions for your dermatologist
Would a blood test change what we do, or only tell me a number?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Is ___ worth trying alongside my current treatment, or is the evidence too thin?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What about going gluten-free, or an anti-inflammatory diet?
Neither is an established vitiligo treatment. The 2020 review of nutrition, supplement and herbal studies I read found the evidence too mixed to set a diet for anyone. The British guideline recommends no diet at all. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Eating in a way that supports your general health is worth doing for the rest of your body. That is general health advice, and a healthy weight belongs in the same category. Neither is vitiligo treatment.
Considerations
- Depends on you
I looked for a trial of a named diet in vitiligo, and found none. That is an absent result rather than a tested one. If your skin changes after a food change, timing alone does not establish the cause.
Questions for your dermatologist
Do I need testing for a food-related condition before I cut ___ out?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What human studies stand behind the ___ diet I keep reading about?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Vitiligo runs with other autoimmune conditions. Does that change what I eat?
It can, but through the other condition rather than through the vitiligo. The British guideline I read recommends thyroid function and antithyroid antibody testing for people with vitiligo. The American Academy of Dermatology says vitiligo raises the risk of some other diseases, such as thyroid disease, and that a dermatologist can monitor for them. Evidence Evidence
Why this matters
- Sources cited, not yet graded
A condition found that way is treated on its own terms. Any food or nutrient advice then belongs to that diagnosis, and it comes from the clinician managing it.
Considerations
- Depends on you
Vitiligo on its own diagnoses nothing else. I checked both sources for a testing schedule or a named nutrient, and neither sets one. Neither says which tests apply to you.
Questions for your dermatologist
Does the guidance you follow recommend blood tests for me now?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If a test comes back abnormal, who manages the food side of it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What should I tell my dermatologist before I add a supplement?
Name every one, including a plain vitamin. I read the National Center for Complementary and Integrative Health page on supplements, and it says evidence and product contents vary widely. It says interactions, contamination and risks tied to a health condition are all possible. Evidence Evidence
Why this matters
- Sources cited, not yet graded
The list matters more once a pill form of a newer drug type joins your plan. The European Medicines Agency safety overview for Rinvoq (upadacitinib), which I read, records EU restrictions that include severe liver problems. That is a reason your clinician wants the full list in front of them.
Considerations
- Depends on you
Neither source checks one product against one medicine, and neither works out risk for you. The European overview is not a US label, and no amount or monitoring plan is set here.
Questions for your dermatologist
Should I stop taking ___ while I am on this treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Do my blood tests need to change because of what I take?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- European Medicines AgencyRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the EMA safety overview, including EU restrictions concerning tuberculosis or another serious infection, severe liver problems, pregnancy, and additional caution when no suitable alternative exists for older adults or people with cardiovascular or cancer risk. It does not calculate personal risk, establish reimbursement, or supply a vitiligo regimen.
What it does not support
The product-information document linked from this page was dated before the July 24, 2026 vitiligo authorization decision and must not be treated as the source of the new vitiligo indication.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Alternative and Complementary Medicine (Shakhbazova A, et al.)Systematic review · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that nutrition, supplement and herbal studies are heterogeneous, often adjunctive and insufficient to establish a universal diet or reliable stand-alone vitiligo treatment.
What it does not support
Commercial independence was not established in this review; it does not establish product equivalence, quality, safety, an individual deficiency or a recommendation to use a reviewed ingredient.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Center for Complementary and Integrative HealthPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports general US consumer context that supplement evidence and product content vary and that interactions, contamination and health-condition risks are possible.
What it does not support
It is not vitiligo-specific efficacy evidence, a product-quality verification service or an individual safety determination.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Cochrane Database of Systematic Reviews (Whitton ME, et al.)Systematic review · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Cochrane reviews are prepared to a published method and are not funded by a maker of any reviewed product.
What this source supports
Supports that 96 randomized trials covering 4,512 people had been published on vitiligo treatment when this review closed its search. Among the analyses of more than 75 per cent repigmentation, one trial of 47 people found oral ginkgo biloba better than placebo. Most included trials enrolled fewer than 50 people. Only five of the 96 reported all three of the review’s primary outcomes, which were quality of life, more than 75 per cent repigmentation, and adverse effects. No included trial measured whether repigmentation was still there two years later.
What it does not support
It reviews trials and does not recommend one. It does not establish any supplement as a treatment, set an amount to take, compare brands or preparations, or predict what one person will get. Its search closed in October 2013, so it cannot speak to anything published after that.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and Venereology (Middelkamp-Hup MA, et al.)Randomized trial · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The published record read here does not state who funded the trial or what relationship the authors had with the extract’s maker, so independence is recorded as not established rather than assumed.
What this source supports
Supports that 50 people with vitiligo vulgaris were randomly assigned to oral Polypodium leucotomos extract or to placebo, each alongside narrowband UVB, for 25 to 26 weeks. Head and neck repigmentation was 44 per cent with the extract and 27 per cent with placebo, which the authors report as P = 0.06. The differences at the trunk, at the arms and legs, and at the hands and feet were between 4 and 6 percentage points and were not significant. The authors describe the head and neck finding as a clear trend.
What it does not support
A P value of 0.06 does not establish the effect. The trial tested one extract taken together with narrowband UVB, so it says nothing about the extract used on its own, about another brand or preparation, or about a site other than the head and neck. The authors suggest the effect may be larger in lighter skin types, which is a suggestion in their discussion and not a finding. It sets no amount and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Scientific Reports (Anam K, et al.)Systematic review · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The review pools published blood measurements and has no product to sell; no maker of a supplement is named as a sponsor in the record read here.
What this source supports
Supports that across 41 studies, 3,353 people with vitiligo and 10,638 people without it, average serum zinc and average serum copper were lower in the vitiligo group and average serum selenium was higher. The review reports very high disagreement between the pooled studies, at 95 per cent for zinc and copper and 97 per cent for selenium on its heterogeneity measure. Its stated conclusion is an association.
What it does not support
Every pooled study measured blood levels rather than treatment, so nothing in it tests whether taking zinc, copper or selenium changes vitiligo. A group average does not establish one person’s level, a deficiency, or a reason to supplement. It sets no amount, does not establish which came first, and does not say what should be tested.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.